// App-Quantinova.ai

: Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation

Researchers

Presenter

  • Mark-Alexander Schwarzbich

Principal Investigators

  • Hao Dai

  • Lambros Kordelas

  • Dietrich W. Beelen

  • Aleksandar Radujkovic

  • Carsten Mller-Tidow

  • Peter Dreger

  • Thomas Luft

Medical Centers

  • Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • Department of Radiology, German Cancer Research Center, Heidelberg, Germany

  • Department of Bone Marrow Transplantation, University Hospital, Essen,

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Leptin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved